Insights

CLSI experts will be attending ADLM 2025 in Chicago, Illinois 27-31 July. Here's your guide to key talks you won't want to miss!

CLSI recently hosted it's June 2025 Committees Week in Frisco, Texas. Here are key highlights from the meetings.

If you missed us on April 29, Testing With Confidence: Evaluation Protocols and Strategies for Compliance, don’t worry. Here’s a recap of key panel discussions and how you can still get involved.

CLSI is hosting the annual AST Committees Week Meeting May 31-June 3rd. This event is vital to the continued collaboration of laboratory professionals dedicated to quality patient care and pushing AST standards forward.

S. maltophilia is a motile gram-negative bacillus, frequently identified as a nosocomial pathogen in individuals with indwelling devices, long-term hospitalization or intensive care unit (ICU) stay, chronic respiratory disease, or an immunocompromising condition.

A 34-year-old patient with quadriplegia was admitted with tachypnea and fever. A diagnostic evaluation for pneumonia was performed, including a molecular pneumonia panel and respiratory cultures on expectorated sputum.

Rezafungin is a novel systemic antifungal agent of the echinocandin class, which was approved by the US Food and Drug Administration (FDA) in March 2023 for the treatment of candidemia and invasive candidiasis in adults with limited treatment options.

Tedizolid disk diffusion breakpoints for staphylococci, beta-hemolytic streptococci and viridans streptococci were added to CLSIM100 in 2024.

CLSI M24 provides a standard method for antimicrobial susceptibility testing (AST) of rapidly growing mycobacteria (RGM), including M. chelonae.1

We spoke with CLSI volunteer Dr. Aleksei Tikhonov, PhD about the vital role CLSI volunteers have in supporting laboratory professionals and ensuring quality across labs worldwide.